NKILT Therapeutics is a new cell therapy biotech developing a novel approach of engineering Natural Killer (NK) cells, and other immune cells, to directly target leukemias and solid tumors.
In vitro proof of concept has been confirmed!
Our initial platform, is a novel Chimeric ILT-Receptor (CIR), featuring a unique proprietary binding technology, targeting the inducible immune checkpoint, HLA-G (expressed in over 50% of human cancers). Our initial armored CIR-NK cells will be able to exquisitely target and directly kill cancer cells but will also activate innate immunity and directly target the tumor’s defense mechanisms.
The first indication will be Acute Myeloid Leukemia (AML) as a clinical proof of concept, expanding rapidly to our core focus in a large array of solid tumors such as Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and more HLA-G+ tumors.
In vitro proof of concept has been confirmed!
Our initial platform, is a novel Chimeric ILT-Receptor (CIR), featuring a unique proprietary binding technology, targeting the inducible immune checkpoint, HLA-G (expressed in over 50% of human cancers). Our initial armored CIR-NK cells will be able to exquisitely target and directly kill cancer cells but will also activate innate immunity and directly target the tumor’s defense mechanisms.
The first indication will be Acute Myeloid Leukemia (AML) as a clinical proof of concept, expanding rapidly to our core focus in a large array of solid tumors such as Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and more HLA-G+ tumors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2021
Main Therapeutic Focus:
Oncology
Lead Product in Development:
CIR-NK cells
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
N/A
Speaker
